SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending as the community reacts to news of a government directive to purchase $200 billion in mortgage bonds, aiming to significantly lower rates. This development is sparking widespread bullish sentiment, with many anticipating a revitalized housing market, increased transaction volume, and potential for a substantial short squeeze on the stock.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies (RKT) is trending following news of former President Trump's plans to stimulate the housing market, including instructing representatives to buy $200 billion in mortgage bonds and potentially banning institutional home purchases. This has ignited community discussion around an impending refinance boom and increased housing affordability, positioning RKT's integrated mortgage and real estate platform for a significant re-rating and potential new highs. Investors are actively debating the magnitude of this positive catalyst on RKT's business model.

flyExclusive, Inc. engages in owning and operating jet aircraft for private jet passengers. It manages all aspects of the customer experience, in-house maintenance, repair, and overhaul services, including paint, interiors, and avionics capabilities. The company was founded by Thomas James Segrave, Jr. in 2015 and is headquartered in Kinston, NC.

flyExclusive Inc. - Ordinary Shares - Class A

flyExclusive is experiencing a surge in attention following its announcement as an authorized Starlink Aviation dealer, which allows the company to install high-speed internet on its private jet fleet and for third-party clients. This development is fueling widespread discussion and speculative trading activity, with the community weighing its potential for new revenue streams against market concerns regarding recent stock offerings.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is trending on confirmed reports that its subsidiary, Airobotics, has been selected as the prime contractor for Israel's significant drone hive border security project. This pivotal role, alongside broader discussions of increased defense spending and strategic partnerships, is fueling immense community optimism regarding its future in autonomous defense systems. Many investors are anticipating continued growth, driven by strong institutional interest and the potential for a "drone super-cycle."

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion Inc. (ACON) is trending after releasing its 2025 update and 2026 corporate outlook, highlighting triple-digit growth for its Nociscan AI back pain platform and a strong financial position with no debt. The community is actively discussing the stock's low float and substantial cash per share, leading to speculation about a significant short squeeze reminiscent of other recent low-float runners. However, some investors remain cautious, citing the company's history of reverse splits and potential dilution concerns.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following disappointing preliminary Q4 results and a significantly lowered DefenCath revenue guidance for 2026 and 2027, primarily due to the anticipated expiration of TDAPA funding, triggering a sharp sell-off and strong community frustration with management. Despite the immediate negative reaction, many bulls see the dip as an overreaction and a buying opportunity, emphasizing that the guidance is conservative and excludes potential upsides from new customers, upcoming legislation like the Kidney Care Access Protection Act, and growth from the broader Melinta Therapeutics portfolio.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae (FNMA) is trending due to recent political statements outlining a directive for the entity to utilize its substantial cash reserves, including $200 billion, to purchase mortgage bonds aimed at lowering interest rates. This move is widely discussed within the community as a significant progression towards resolving long-standing issues and potentially paving the way for its release from conservatorship and eventual public offering. Investors are actively debating the implications of this strategy for the housing market and the entity's future, with many anticipating a major shift.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending after its market capitalization was recently surpassed by Alphabet, intensifying debates around its AI strategy following a multi-day stock pullback. The community is sharply divided, with many viewing the stock as oversold and a buying opportunity ahead of anticipated earnings and a key Supreme Court tariff decision, while others question its innovation trajectory.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

DIA is capturing attention as major geopolitical developments involving the US and Venezuela, including an oil deal and leadership changes, coincide with an awaited Supreme Court ruling on tariffs and a key jobs report. Community sentiment is divided between celebrating the Dow's impressive new highs and cautioning against a potentially unsustainable rally driven by these significant, market-moving events and broader blue-chip sector dynamics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ariose Capital Management Ltd Invests $5.37 Million in Vor Biopharma Inc. $VOR

Ariose Capital Management Ltd acquired a new stake in Vor Biopharma Inc. (NASDAQ:VOR - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities...

Vor Biopharma Target of Unusually High Options Trading (NASDAQ:VOR)

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) was the recipient of some unusual options trading on Friday. Stock traders acquired 4,176 put options on the stock. This is an increase of 196...

Vor Biopharma Inc. (NASDAQ:VOR) Receives Average Rating of "Moderate Buy" from Analysts

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen brokerages that are presently covering the stock, Marketbeat reports. One analyst...

Vor Biopharma Inc. (NASDAQ:VOR) Sees Large Growth in Short Interest

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 1,943,561 shares, an...

JPMorgan Chase & Co. Issues Pessimistic Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price

JPMorgan Chase & Co. reduced their price objective on shares of Vor Biopharma from $43.00 to $40.00 and set an "overweight" rating for the company in a report on Friday...

Vor Biopharma (NASDAQ:VOR) Earns Buy Rating from Analysts at TD Cowen

TD Cowen started coverage on shares of Vor Biopharma in a research report on Wednesday. They issued a "buy" rating for the company...

Manufacturing Stocks To Keep An Eye On - December 9th

Taiwan Semiconductor Manufacturing, Applied Materials, and Vor Biopharma are the three Manufacturing stocks to watch today, according to MarketBeat's stock screener tool. Manufacturing stocks are...

Vor Biopharma (NASDAQ:VOR) Now Covered by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on Vor Biopharma in a research report on Tuesday. They set an "overweight" rating and a $43.00 price objective for the company...

<ul class="summary-bullets"><li>Vor Biopharma shares surged over&nbsp;40%&nbsp;after JPMorgan initiated coverage of the company.&nbsp;</li><li>JPMorgan’s bullish stance comes amid Phase 3 clinical trial success for an autoimmune drug, telitacicept.&nbsp;</li><li>On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ while message volume rose to ‘extremely high’ levels.</li></ul>Shares of Vor Biopharma Inc. (VOR) rallied over 40% on Tuesday in premarket trading after JPMorgan initiated coverage of the clinical-stage biopharma company with a bullish stance.&nbsp;In a note on Tuesday, as cited by TheFly, JPMorgan awarded&nbsp;<a href="https://stocktwits.com/symbol/VOR">VOR</a> with an ‘Overweight’ rating and set a price target of $43. The firm said that it views VOR’s telitacicept, a recombinant fusion protein that is intended to treat autoimmune diseases, as "highly de-risked" across a range of indications.&nbsp;<h2 class="st-heading-2">Tapping Market Gaps</h2>JPMorgan’s coverage comes amid the pharma company’s success in its autoimmune disease treatment plans. In its latest quarterly results, VOR noted that telitacicept has “demonstrated consistent results on multiple efficacy endpoints, durable benefit, and a favorable safety profile”.&nbsp;VOR has a "significant valuation disconnect", JPMorgan said in its note, highlighting the probability-adjusted value of telitacicept to treat chronic conditions of myasthenia gravis and primary Sjogren's disease alone. The firm added that VOR, while focused on global indications that are less competitive, still has an unmet need that is significant.&nbsp;In other news, Vor Biopharma&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.vorbio.com/news-releases/news-release-details/vor-bio-announces-pricing-public-offering-100-million-common">announced</a> a $100 million public offering of common stock priced at $10 per share in November.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VOR jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1286/155;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_09_at_6_11_06_PM_png_fd2a6ad6c4.webp" alt="On Stocktwits, retail sentiment around VOR jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels." width="1286" height="155"></figure>One user on the platform predicted that VOR’s share price could go up to $20. The stock was trading around $10 at the time of writing.&nbsp;<a href="https://stocktwits.com/apux/message/638580684">https://stocktwits.com/apux/message/638580684</a>Shares of VOR have fallen almost 60% in the past one year.For updates and corrections, email newsroom[at]stocktwits[dot]com&nbsp;

Young female scientist working in laboratory (Representative image courtesy of Solskin via Getty Images)

VOR Shares Rally Over 40% In Pre-Market Trade After JPMorgan Initiates Bullish Coverage 

The firm gave Vor Biopharma an ‘Overweight’ rating with a price target of $43. 

VOR Shares Rally Over 40%In Pre-Market Trade After JPMorgan Initiates Bullish Coverage 

Equity

The firm gave Vor Biopharma an ‘Overweight’ rating with a price target of $43. 


<ul class="summary-bullets"><li>All eyes are on the Fed’s rate decision scheduled for Wednesday.&nbsp;</li><li>NVIDIA is in the spotlight after President Donald Trump declared on Monday that the U.S. will allow it to ship its H200 chips to China and other countries upon fulfillment of certain conditions, even as reports emerge of Beijing limiting access.</li><li>Retail sentiment on Stocktwits for the S&amp;P 500 ETF and Invesco QQQ was in the ‘bearish’ territory.</li></ul>U.S. equities are treading cautiously in Tuesday’s premarket session as investors await the Fed’s key rate policy decision due on Wednesday.While Dow Jones futures were up by 0.11% at the time of writing, the S&amp;P 500 futures rose 0.04% while the Nasdaq 100 futures declined 0.03%.&nbsp;The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY) was up by 0.06%,&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ) edged 0.03% lower, and&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) rose 0.11% in premarket. Retail sentiment around the S&amp;P 500 ETF and Invesco QQQ on Stocktwits was in the ‘bearish’ territory.<h2 class="st-heading-2">Fed Rate Anticipation</h2>While the market expects a 25-basis-point cut, uncertainty about fresh tariffs on Mexico, Canada, and India is also affecting investor sentiment.&nbsp;There is an 89.4% probability of a 25 basis point rate cut this week, according to the latest data from the&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">CME FedWatch</a> tool. Last week, Morgan Stanley joined peers JPMorgan and Bank of America (BofA) to revise its expectations and reiterate a 25-basis-point cut from its previous expectation of a status quo policy.<h2 class="st-heading-2">Stocks To Watch</h2>Nvidia (NVDA): The chip giant is in the spotlight after President Donald Trump declared on Monday that the U.S. will allow it to ship its H200 chips to China and other countries upon fulfillment of certain conditions, even as reports emerge of Beijing limiting access. Shares of&nbsp;<a href="https://stocktwits.com/symbol/NVDA">NVDA</a> are up 1.7% in premarket trading.Vor Biopharma (VOR):&nbsp;<a href="https://stocktwits.com/symbol/VOR">VOR shares</a> are up over 26% at the time of writing due to positive sentiment around a recent Phase 3 clinical study. JPMorgan has initiated coverage on Vor Bio with a bullish view.Exicure Inc (XCUR): The early-stage biotech company&nbsp;<a href="https://stocktwits.com/symbol/XCUR">XCUR</a> is up over 77% in premarket trading because of positive Phase 2 trial results for its cancer treatment.GameStop (GME), Dave &amp; Buster's (PLAY), Core &amp; Main Inc (CNM), SailPoint Technologies (SAIL), and Casey's General Stores (CASY) are among the companies scheduled to report their latest quarterly earnings on Tuesday.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The New York Stock Exchange (NYSE) stands off Wall Street on April 17, 2025 in New York City. (Photo by Spencer Platt/Getty Images)

Futures Tread Cautiously Pre-Market As Investors Await Key Fed Decision: NVDA, XCUR, GME, CASY Among Stocks To Watch

The Dow Jones futures were up by 0.11% while the S&P 500 futures were up 0.04%. 

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.

Vor Biopharma Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.00	--	--	N/A
Q3 '25	-$3.45	-$121.63	-3422.95%	MISSED
Q2 '25	-$0.26	-$251.22	-96523.09%	MISSED
Q1 '25	-$0.25	--	--	N/A
Q4 '24	-$0.29	-$0.44	-54.00%	MISSED

VOR
Vor Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest VOR News

VORVor Biopharma Inc